📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Module 2.7.2 — Summary of Clinical Pharmacology Studies (OBX-319)

Document ID: M272
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): ICH M4E / M10

2.7.2 Summary of Clinical Pharmacology Studies — OBX-319

OBX-319 is a humanized bispecific IgG1 monoclonal antibody that simultaneously engages CD19 and CD20 on B lymphocytes to produce deep B-cell depletion. It is expressed in recombinant Chinese hamster ovary (CHO) cell culture, purified by a Protein A capture and polishing downstream train, and administered by subcutaneous (SC) injection. Its clinical pharmacology was characterised across the development programme and integrated into a population pharmacokinetic/pharmacodynamic (PK/PD) analysis that supports the doses studied in the pivotal Phase 3 study OBX319-301 (randomized, double-blind, placebo-controlled, 1:1:1, 52 weeks; N = 480 [162 OBX-319 High, 158 OBX-319 Low, 160 Placebo]) in moderate-to-severe active SLE (baseline SLEDAI-2K ~11) on background standard of care. Because OBX-319 does not cross-react with rodent antigens, the cynomolgus monkey was the sole pharmacologically relevant species nonclinically (ICH S6(R1)), and the human dose rationale, PK expectations, and pharmacodynamic (B-cell depletion) targets were bridged from that species. As an intact immunoglobulin, OBX-319 is not subject to classical small-molecule metabolism, and no genotoxicity, carcinogenicity, hERG, or thorough-QT evaluation is warranted for this modality. Bioanalytical (drug and anti-drug antibody) methods were validated in accordance with ICH M10, and the biologic is developed as a BLA under 21 CFR 601 with the quality control strategy governed by ICH Q5A(R2)/Q5C/Q6B.

Pharmacokinetics

Subcutaneous absorption with typical IgG bioavailability; target-mediated drug disposition (TMDD) producing non-linear PK at low concentrations; distribution largely confined to plasma and interstitial fluid; elimination by proteolytic catabolism and (in the target-mediated component) receptor-mediated clearance. Classical small-molecule ADME (mass balance, CYP/transporter) is not applicable to an intact IgG. Exposure was characterised across the dose levels evaluated in OBX319-301 (OBX-319 High, OBX-319 Low, Placebo).

Absorption. Following SC administration, OBX-319 is absorbed slowly through the lymphatic system with first-order kinetics, giving a delayed time-to-peak concentration and the incomplete, partly presystemic-catabolism-limited bioavailability characteristic of therapeutic IgG1 antibodies. Absorption rate rather than elimination is expected to govern the terminal phase after SC dosing (flip-flop kinetics), and injection-site tolerability was monitored alongside PK.

Distribution. Consistent with the physicochemical properties of a ~150 kDa immunoglobulin, distribution is largely restricted to the plasma and interstitial (extracellular) fluid compartments, with a small central volume approximating plasma volume and limited tissue penetration except at sites of high target (B-cell) density, including secondary lymphoid tissue.

Elimination and the target-mediated (TMDD) component. Two parallel elimination pathways operate. A linear, non-specific pathway reflects reticuloendothelial proteolytic catabolism modulated by neonatal Fc receptor (FcRn)-mediated recycling, which confers the prolonged systemic persistence typical of IgG1. A saturable, non-linear pathway reflects receptor-mediated (CD19/CD20 target-mediated) internalisation and clearance. At low concentrations and high B-cell burden the target-mediated pathway predominates and clearance is high; as peripheral and tissue B cells are depleted the target sink collapses, the TMDD contribution wanes, and disposition becomes progressively more linear over the dosing interval. Consequently, exposure increased in a greater-than-dose-proportional manner between the Low and High dose levels as the saturable clearance pathway approached saturation, and steady-state accumulation reflects the long catabolic half-life once the target sink is minimised.

Population PK and covariates. A two-compartment model with parallel first-order (linear) and Michaelis-Menten (saturable) clearance and first-order SC absorption described the data. Rich-sampling Phase 1/2 profiles were combined with sparse sampling from OBX319-301 to estimate individual exposures for the exposure-response analysis. Body weight was the principal structural covariate on clearance and volume; anti-drug-antibody-positive status was associated with increased clearance and lower exposure in a subset of subjects. Baseline B-cell burden and disease activity were evaluated as determinants of the target-mediated clearance component.

Intrinsic and extrinsic factors. Intact IgG1 is not renally filtered and is not metabolised by cytochrome P450 enzymes or hepatic transporters; accordingly, no clinically meaningful effect of mild-to-moderate renal or hepatic impairment on OBX-319 clearance is anticipated, and no dedicated dose adjustment for these organ-impairment categories is expected. Age, sex, and race were assessed within the population PK covariate analysis. Because clearance and elimination do not involve CYP/transporter pathways, the potential for pharmacokinetic drug-drug interactions is low; therapeutic-protein interaction risk (e.g., cytokine-mediated CYP modulation) is not expected to be clinically relevant for a B-cell-depleting agent. The principal extrinsic pharmacodynamic consideration is attenuation of humoral responses to concomitant vaccines during B-cell depletion, with live/live-attenuated vaccines to be avoided.

Pharmacodynamics / Exposure-response

The exposure-response relationship supports the dose selection for SRI-4 response at Week 52 (operationalised as low disease activity, SLEDAI-2K <= 4).

Primary pharmacodynamic marker — B-cell depletion. Circulating CD19+ B-cell counts, measured by a validated flow-cytometry method, are the primary pharmacodynamic biomarker. Both active arms produced near-complete peripheral B-cell depletion (approximately 210 → 7 cells/µL), whereas counts were essentially unchanged on placebo. Dual, simultaneous engagement of CD19 and CD20 is mechanistically central: it broadens coverage to B-cell subsets that can escape single-antigen therapy — including CD20-low or CD20-negative plasmablasts and CD19-expressing early B-lineage and antibody-secreting cells — yielding deeper and more uniform depletion and redundancy against antigen-loss escape.

Secondary pharmacodynamic and disease biomarkers. In association with clinical response, anti-dsDNA autoantibody titres declined and the complement components C3 and C4 normalised, consistent with interruption of autoreactive B-cell drive and reduced immune-complex-mediated consumption. Serum immunoglobulins (IgG/IgM/IgA) were monitored longitudinally because sustained B-cell depletion carries a class risk of hypogammaglobulinaemia and consequent susceptibility to serious and opportunistic infection.

Time course and reversibility. Depletion was rapid (onset within days to a few weeks of the first SC doses) and was sustained throughout the dosing period; peripheral B-cell repopulation is expected upon treatment cessation as marrow output resumes, providing the pharmacodynamic basis for infection-risk mitigation and re-treatment strategies.

Exposure-response for efficacy. Both dose levels separated clearly from placebo for the Week 52 low-disease-activity endpoint (SLEDAI-2K <= 4): 52.4% (76/145) for OBX-319 High, 33.8% (49/145) for OBX-319 Low, and 6.0% (9/150) for Placebo. The corresponding LS-mean change from baseline in SLEDAI-2K was -6.37 (High), -5.62 (Low), and -3.46 (Placebo), giving placebo-adjusted differences of -2.91 and -2.17. Although peripheral B-cell depletion was near-maximal at both dose levels, the dose-ordered clinical benefit indicates that maintenance of adequate exposure and depletion of tissue/germinal-centre B-cell compartments — rather than peripheral B-cell count alone — drive the incremental response at the High dose. Taken together, the exposure-response analysis supports selection of the OBX-319 High dose for the intended indication.

Exposure-safety. Exposure was examined against the class-relevant identified risks of B-cell depletion — serious and opportunistic infection and hypogammaglobulinaemia — and against injection/infusion reactions and immunogenicity; no exposure threshold indicating an unfavourable benefit-risk shift within the studied range was identified.

Cardiac repolarisation. A dedicated thorough-QT/concentration-QTc (E14) study and nonclinical hERG/S7B assessment are not warranted for a monoclonal antibody of this class, which has no expectation of direct cardiac ion-channel interaction, consistent with the ICH E14/S7B question-and-answer framework for biologics.

Immunogenicity

Anti-drug antibody (binding and neutralising) assessment is integral; immunogenicity may affect exposure and is characterised with a tiered validated assay strategy. The tiered scheme (screening → confirmatory → titre → neutralising-antibody characterisation) was implemented with a bridging electrochemiluminescence format validated per ICH M10 for sensitivity, drug tolerance, and target (soluble-antigen) interference. Because OBX-319 is a bispecific, anti-drug antibody responses were characterised against each binding domain/idiotype (anti-CD19 and anti-CD20 arms) and against potential novel junctional epitopes at the bispecific interface. Incidence, time of onset, and persistence (transient versus persistent) were reported, together with the impact of confirmed anti-drug antibodies on pharmacokinetics (increased clearance and reduced exposure), pharmacodynamics (attenuated or abrogated B-cell depletion), clinical efficacy, and safety (including hypersensitivity and injection-site reactions). Neutralising capacity was assessed with a competitive ligand-binding/cell-based assay in confirmed-positive samples. Notably, profound B-cell depletion may itself blunt de novo humoral anti-drug antibody formation, a factor considered in interpreting observed immunogenicity rates.

Guidelines: ICH M10, E14/S7B (as applicable).